Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.

Piramal Pharma forays into men's grooming market in India with the launch of BOHEM

Cupid to supply Rs. 23.07 crore female condoms in Brazil

Total value of the supplies of FC will be US$ 2.773 million

KRAZATI in Combination with Cetuximab demonstrates targeted treatment option for KRAS G12C- colorectal cancer

Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program

Syntegon showcases oral solid dosage portfolio at Achema

Fluid bed processes: drying, granulating, and coating in just one product container

Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development

The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility

SPARC announces results from planned interim analysis of PROSEEK Study

Pluss unveils Celsure XL VIP pallets

A game changing solution for the pharmaceutical industry

Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData

The approval marks a significant milestone for the American pharmaceutical company in the field of UC

Enhertu approved in the US as first tumour-agnostic HER2-directed therapy

Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers